A Beta-only IL-2 ImmunoTherapY Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Unresectable Solid Tumor|Clear Cell Renal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer Squamous|Non-Small Cell Lung Cancer Non-squamous|Colorectal Cancer (MSI-H)|Gastric Cancer|Cervical Cancer|Basal Cell Carcinoma|Bladder Cancer|Merkel Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|Cutaneous Squamous Cell Carcinoma|Pleural Mesothelioma|Esophageal Cancer|Hepatocellular Carcinoma|Endometrial Carcinoma|Solid Tumor|Solid Tumor, Adult|MSI-H Solid Malignant Tumor|Cancer With A High Tumor Mutational Burden|Epithelial Ovarian Carcinoma|Primary Peritoneal Cancer|Gastroesophageal Junction (GEJ) Cancer|Acral Melanoma|Mucosal Melanoma|Cutaneous Melanoma|DMMR Solid Malignant Tumor|Fallopian Tube Cancer
Interventions: DRUG: MDNA11|DRUG: Pembrolizumab
Sponsor: Medicenna Therapeutics, Inc.
Collaborators: Merck Sharp & Dohme LLC